Innoser Menu
As of 1 January 2019 we will no longer be accessible by phone via our Dutch number. You can reach us via 32 (0) 11 28 69 00 or

Newsletter October 2019


Eurostars grant for MINDMAP

53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat patients, a number of limitations hold the developments back, leaving patients and their families under the high burden of the disease. These limitations include:

  • Not being able to translate our knowledge from animal models to humans optimally
  • Failure in late stage development being extremely costly, which already made the first pharmaceutical company stop their AD research activities. 

To break the deadlock and boost the AD drug development, researchers and industry are in urgent need of novel in vitro models that can assess the safety and efficacy in the human brain in early stage development.

Towards a solution with brain-on-a-chip

We are happy to announce that InnoSer received a new Eurostars grant for the development of MINDMAP, an in vitro model for neuronal activity in healthy and Alzheimer’s Disease-affected human brains. 3D cultures of human stem cell-derived neurons will be integrated in a microfluidic chip, delivering a brain-on-a-chip (BoC) technology.

Combining the BoC with dynamic optical imaging functionalities, MINDMAP will be the first capable technology of generating sensitive high-resolution readouts of neuronal network activity at single-cell level. This novel 3D in vitro model will be offered as a service for testing compounds against Alzheimer’s Disease.

This project will develop MINDMAP to decrease the failure rate in the clinical phase and boost the development of drugs against AD. Moreover, it provides a solid basis for furthering our understanding of neurodegenerative diseases.

New cell culture facilities

InnoSer is expanding its infrastructure to better its in vitro services. Soon, we will be able to work with both human and animal cell lines separately.

These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh tissue from the clinic, cell lines or organoids.

We offer different analysis methods including viability assays, cell proliferation assays, cytokine multiplex, ELISA, and Flow cytometric analyses.

We will also have 2 full time research technicians working on the in vitro activities under the guidance of a study director, who is in direct contact with our clients.

Leader in PKD mouse model

Polycystic kidney disease (PKD) is a genetic disorder with a prevalence of up to 1:3000. Fluid filled cysts develop in the kidneys of PKD patients, causing the kidneys to enlarge and lose function over time. PKD can cause serious complications due to the disturbed urinary clearance, including high blood pressure and ultimately kidney failure. Interventions that slow the progression of the disease can help improve patients' quality of life and reduce costs.

InnoSer is involved in a scientific consortium that focuses on a proof-of-concept to deliver novel treatments for PKD. In this consortium, InnoSer performs key translational studies by screening therapeutic efficacy of lead compounds. Successful lead compounds are tested in unique PKD animal models to validate their therapeutic efficacy in vivo.

Upcoming Events

Bio and medical technology companies are gathering in Geleen this October at the ''Biomedica On The Move'' event to nourish innovation and collaboration in the field. InnoSer is happy to also attend the meeting and is looking forward to building bridges for brighter futures.

From kidney disease genetics to regenerative medical interventions, a wide range of topics are covered in November 2019 edition of American Society of Nephrology’s ''Kidney Week''. 12,000 kidney professionals will exchange their latest research results, develop new collaborations and engage in provocative discussion. Come meet InnoSer in booth number 2837 during the Scientific Exposition session in this dynamic meeting.

Beautiful city of Leuven, Belgium, will host the 2nd edition of the European Conference on Novel Technologies for In Vitro Diagnostics, DIATECH 2020. In order to join to and learn from the discussions on the development of new diagnostic tools, innovative devices and molecular technologies, InnoSer is going to be present at DIATECH.